Omnia SanaPlant Comparison
Horse Chestnut vs Common Comfrey
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Horse Chestnut and Common Comfrey: they share 6 indicated uses (arthritis / joint pain, inflammation (general), pain (general), …); 2 pharmacological actions in common.
Evidence face-off — shared uses
| Condition | Horse Chestnut | Common Comfrey | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 2/10 | 5/10 | Stronger for Common Comfrey |
| Inflammation (general) | 2/10 | 5/10 | Stronger for Common Comfrey |
| Pain (general) | 7/10 | 8/10 | Comparable evidence |
| Skin irritation | 2/10 | 5/10 | Stronger for Common Comfrey |
| Swelling / fluid retention | 7/10 | 5/10 | Stronger for Horse Chestnut |
| Varicose veins | 7/10 | 5/10 | Stronger for Horse Chestnut |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
The active mixture responsible for the venotonic and anti-oedematous effects; extracts are standardised to it. Escin is available as oral drages and a transdermal gel, with efficacy shown in chronic venous insufficiency and blunt-trauma injury.
The key cell-proliferative constituent underlying comfrey's wound-healing reputation.
Contribute to the soothing, demulcent texture of the leaf and root.
Contribute to antioxidant and anti-inflammatory activity.
Hepatotoxic constituents naturally present in the whole plant; the reason internal use is not recommended and processed/detoxified extracts are used for research.
Pharmacological Actions
Anti-oedematous and anti-inflammatory - escin reduces vascular permeability in inflamed tissue and exerts venotonic effects on veins
Anti-oedematous and anti-inflammatory - escin reduces vascular permeability in inflamed tissue and exerts venotonic effects on veins
Escin, the triterpene saponin of Aesculus hippocastanum, induces apoptosis and cell-cycle arrest and chemosensitizes breast, hepatocellular, lung and pancreatic cancer cells (preclinical, including in vivo xenograft models).
Traditional & Indicated Uses
inferred from anti-inflammatory action
Escin shows antiproliferative and pro-apoptotic activity and enhances chemotherapy/immunotherapy efficacy in breast (MCF-7), hepatocellular, lung and pancreatic cancer models; it modulates NF-kappaB, p53, p38 MAPK/ERK and PD-L1 (preclinical).
Relief of haemorrhoid symptoms (venotonic)
inferred from anti-inflammatory action
Chronic venous insufficiency - reduces leg pain, swelling (oedema), heaviness and itching; supports varicose veins
inferred from anti-inflammatory action
Chronic venous insufficiency - reduces leg pain, swelling (oedema), heaviness and itching; supports varicose veins
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from anti-oedematous action
Safety, Cautions & Contraindications
Use only standardised, processed seed extract. Raw conkers, leaves and bark contain toxic esculin and can cause poisoning - never eat raw horse chestnut.
May increase bleeding risk, so use caution with anticoagulant/antiplatelet medicines; use caution in kidney disease and avoid in pregnancy and breastfeeding.
Big headline: Comfrey naturally contains pyrrolizidine alkaloids (PAs), which can seriously harm the liver if taken internally (Staiger, 2012; EMA, 2015). • Do not ingest comfrey (no teas, no internal tinctures, no capsules), because PA exposure from internal use is the main safety problem (Staiger, 2012; Bach et al., 1990). • Topical use only, short-term: EU herbal guidance describes comfrey root preparations for minor bruises and sprains in adults, and recommends limited duration (commonly up to about 10 days) (EMA, 2015; EMA/HMPC, 2024). • Do not apply to broken skin (open wounds, damaged/irritated skin) and avoid eyes/mucous membranes (EMA/HMPC, 2024). • Pregnancy & breastfeeding: best avoided (not enough safety margin for medicinal use) (EMA/HMPC, 2024). • Children/adolescents: not recommended for medicinal topical use in EU monograph context (EMA/HMPC, 2024). • If you have liver disease or take medicines that stress the liver, skip comfrey completely (risk management logic based on PA concern) (Staiger, 2012; EMA, 2015). • Skin reactions: mild rash/irritation can occur; stop if it irritates (Smith and Jacobson, 2011).
Duke (2002) classifies common comfrey (Symphytum officinale) with anti-inflammatory and wound-healing properties, supported by allantoin content (promotes cell proliferation). However, comfrey also contains hepatotoxic pyrrolizidine alkaloids. Internal use is no longer recommended, and Commission E approved only external use. Duke emphasizes that pyrrolizidine alkaloids are cumulative hepatotoxins associated with veno-occlusive disease, and prolonged or internal use is contraindicated (Duke, 2002).
External Ids
Botanical Description
Large deciduous tree, to 25-30 m, with a broad domed crown and stout, upward-arching branches. The leaves are opposite and palmately compound, with five to seven large, obovate, toothed leaflets radiating from a long stalk. In spring the tree bears large, showy, upright pyramidal flower spikes ('candles') of white flowers marked with yellow or pink at the base. The glossy brown seeds ('conkers') develop inside a spiky green husk and fall in autumn.[1]
Robust, hairy perennial herb (Boraginaceae), 60-120 cm tall, with a thick, black-skinned, mucilaginous taproot. Leaves are large, broad, lance-shaped and bristly-hairy, running down the stem as raised wings (decurrent) - the leaf base's smooth, untoothed margin is a key feature distinguishing it from toxic foxglove. Drooping clusters of tubular, bell-shaped flowers are cream, pink or purple depending on variety.[11]
Habitat
Harvesting
Leaves are cut during the growing season (before flowering is often preferred for lower pyrrolizidine-alkaloid content); root is dug in autumn or spring from mature plants.[11]
Traditional Uses
Horse chestnut seed has a long folk history as a remedy for varicose veins, haemorrhoids and 'heavy legs', and was also used topically for rheumatic pain and bruising. Modern use is almost exclusively as a standardised seed extract for chronic venous insufficiency, confirming this traditional venous-support reputation.[1]
Comfrey has one of the strongest traditional reputations of any European herb for wound healing and bone/tissue repair - the folk names 'knitbone' and 'boneset' reflect this - owing to its high allantoin content, which stimulates cell proliferation. Because the plant also contains hepatotoxic pyrrolizidine alkaloids, modern regulatory use is restricted to topical preparations only, for minor bruises and sprains, and internal use (teas, tinctures) is no longer recommended.[11]
Preparations
The officially recognised European herbal-monograph preparation, for minor bruises and sprains, short-term use only.
Dosage
Clinical studies commonly use extracts standardised to around 100-150 mg escin daily, in divided doses. Educational reference only, not a prescription.
The EU herbal monograph gives semi-solid dosage forms containing the equivalent of 0.4% triterpene glycosides calculated as protoaescigenin (or, depending on the preparation, 0.85-20% herbal preparation), applied as a thin layer to the affected area 1-3 times daily, in adults and elderly. Educational reference only, not a prescription.
EU herbal-monograph guidance describes comfrey root preparations applied topically for minor bruises and sprains in adults, for a limited duration (commonly up to about 10 days); do not apply to broken skin or near eyes/mucous membranes. Comfrey must never be taken internally (no teas, tinctures or capsules) because of its pyrrolizidine alkaloid content. Educational reference only, not a prescription.
References
Drug Class Interactions
Not documented
Lookalikes Review
Dangerous Lookalikes
Not documented
References & Sources
- Idris, S. and Mishra, A. and Khushtar, M (2020) 'Phytochemical, ethnomedicinal and pharmacological applications of escin from Aesculus hippocastanum L. towards future medicine', Journal of Basic and Clinical Physiology and Pharmacology, 31(5). doi:10.1515/jbcpp-2019-0115 Meta-analysis / review
https://doi.org/10.1515/jbcpp-2019-0115 - Penaranda Figueredo, F.A. and Vicente, J. and Barquero, A.A. and Bueno, C.A (2024) 'Aesculus hippocastanum extract and the main bioactive constituent beta-escin as antivirals agents against coronaviruses, including SARS-CoV-2', Scientific Reports, 14(1), pp. 6418. doi:10.1038/s41598-024-56759-y Preclinical
https://doi.org/10.1038/s41598-024-56759-y - Idris, S. and Mishra, A. and Khushtar, M (2023) 'Phytochemical Estimation and Therapeutic Amelioration of Aesculus hippocastanum L. Seeds Ethanolic Extract in Gastric Ulcer in Rats Possibly by Inhibiting Prostaglandin Synthesis', Chinese Journal of Integrative Medicine, 29(9), pp. 818-824. doi:10.1007/s11655-023-3734-9 Preclinical
https://doi.org/10.1007/s11655-023-3734-9 - Quarta, S. and Santarpino, G. and Carluccio, M.A. and Calabriso, N. and Scoditti, E. and Siculella, L. and Damiano, F. and Maffia, M. and Verri, T. and De Caterina, R. and Massaro, M (2022) 'Analysis of the Anti-Inflammatory and Anti-Osteoarthritic Potential of Flonat Fast, a Combination of Plant Extracts, Bromelain and Escin (Aesculus hippocastanum), Evaluated in In Vitro Models of Inflammation Relevant to Osteoarthritis', Pharmaceuticals, 15(10), pp. 1263. doi:10.3390/ph15101263 Preclinical
https://doi.org/10.3390/ph15101263 - Owczarek, A. and Kolodziejczyk-Czepas, J. and Wozniak-Serwata, J. and Magiera, A. and Kobiela, N. and Wasowicz, K. and Olszewska, M.A (2021) 'Potential Activity Mechanisms of Aesculus hippocastanum Bark: Antioxidant Effects in Chemical and Biological In Vitro Models', Antioxidants, 10(7), pp. 995. doi:10.3390/antiox10070995 Preclinical
https://doi.org/10.3390/antiox10070995 - Cheong, D.H.J., Arfuso, F., Sethi, G., Wang, L., Hui, K.M., Kumar, A.P. and Tran, T (2018) 'Molecular targets and anti-cancer potential of escin', Cancer Letters. doi:10.1016/j.canlet.2018.02.027 Preclinical
https://doi.org/10.1016/j.canlet.2018.02.027 - Pittler, M.H. and Ernst, E (2012) 'Horse chestnut seed extract for chronic venous insufficiency', Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD003230.pub4 Meta-analysis / review
https://doi.org/10.1002/14651858.CD003230.pub4 - Gallelli, L (2019) 'Escin: a review of its anti-edematous, anti-inflammatory, and venotonic properties', Drug Design, Development and Therapy, pp. 3425--3437. doi:10.2147/DDDT.S207720 Preclinical
https://doi.org/10.2147/DDDT.S207720 - Wu, X.J., Zhang, M.L., Cui, X.Y., Gao, F., He, Q., Li, X.J., Zhang, J.W., Fawcett, J.P. and Gu, J.K (2011) 'Comparative pharmacokinetics and bioavailability of escin Ia and isoescin Ia after administration of escin and of pure escin Ia and isoescin Ia in rat', Journal of Ethnopharmacology, 139(1), pp. 201--206. doi:10.1016/j.jep.2011.11.003 Preclinical
https://doi.org/10.1016/j.jep.2011.11.003 - European Medicines Agency (HMPC) (2023) 'European Union herbal monograph on Aesculus hippocastanum L., semen, Revision 1'. Available at: https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-aesculus-hippocastanum-l-semen-final-revision-1_en.pdf Traditional / reference
https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-aesculus-hippocastanum-l-semen-final-revision-1_en.pdf - Cheong, D.H.J., Arfuso, F., Sethi, G., Wang, L., Hui, K.M., Kumar, A.P. and Tran, T (2018) 'Molecular targets and anti-cancer potential of escin', Cancer Letters, pp. 1--8. doi:10.1016/j.canlet.2018.02.027 Preclinical
https://doi.org/10.1016/j.canlet.2018.02.027 - Mazrouei, R. and Raeisi, E. and Lemoigne, Y. and Heidarian, E (2019) 'Activation of p53 Gene Expression and Synergistic Antiproliferative Effects of 5-Fluorouracil and beta-escin on MCF7 Cells', Journal of Medical Signals and Sensors, 9(3), pp. 196-203. doi:10.4103/jmss.JMSS_44_18 Preclinical
https://doi.org/10.4103/jmss.JMSS_44_18 - Yuan, Y. and Wang, P. and Chen, S. and Cao, Z. and Ojha, S.C. and Sun, C. and Wang, G. and Wang, Z. and Gu, J. and Kang, J. and Xue, X (2025) 'Escin inhibits PD-L1 expression by suppressing the p38 MAPK/ERK signalling pathways and synergistically enhances PD-1 inhibitor efficacy in hepatocellular carcinoma', Phytomedicine, 149, pp. 157532. doi:10.1016/j.phymed.2025.157532 Preclinical
https://doi.org/10.1016/j.phymed.2025.157532 - Hussain, Y. and Singh, J. and Meena, A. and Sinha, R.A. and Luqman, S (2023) 'Escin enhanced the efficacy of sorafenib by autophagy-mediated apoptosis in lung cancer cells', Phytotherapy Research, 37(10), pp. 4819-4837. doi:10.1002/ptr.7948 Preclinical
https://doi.org/10.1002/ptr.7948 - Rimmon, A. and Vexler, A. and Berkovich, L. and Earon, G. and Ron, I. and Lev-Ari, S (2013) 'Escin Chemosensitizes Human Pancreatic Cancer Cells and Inhibits the Nuclear Factor-kappaB Signaling Pathway', Biochemistry Research International, 2013, pp. 251752. doi:10.1155/2013/251752 Preclinical
https://doi.org/10.1155/2013/251752 - Domanski, D., Zegrocka-Stendel, O., Perzanowska, A., Dutkiewicz, M., Kowalewska, M., Grabowska, I., Maciejko, D., Fogtman, A., Dadlez, M. and Koziak, K (2016) 'Molecular Mechanism for Cellular Response to beta-Escin and Its Therapeutic Implications', PLoS One, 11(10). doi:10.1371/journal.pone.0164365 Preclinical
https://doi.org/10.1371/journal.pone.0164365 - Gloviczki, M.L., Kakkos, S.K., Urbanek, T., Chuback, J. and Nicolaides, A (2025) 'The role of venoactive compounds in the treatment of chronic venous disease', Journal of Vascular Surgery: Venous and Lymphatic Disorders, 13(5). doi:10.1016/j.jvsv.2025.102258 Preclinical
https://doi.org/10.1016/j.jvsv.2025.102258 - Santiago, F.R., Grillo, L., Amore, M., Carmelino, C., Trejo, J.M.R. and Ulloa, J.H (2026) 'Venoactive drugs in the management of chronic venous disease: A critical appraisal of the evidence and comparison with international guidelines', Vascular Pharmacology. doi:10.1016/j.vph.2026.107614 Preclinical
https://doi.org/10.1016/j.vph.2026.107614 - Pittler, M.H. and Ernst, E (2006) 'Horse chestnut seed extract for chronic venous insufficiency', Cochrane Database of Systematic Reviews, 2006(1), pp. CD003230. doi:10.1002/14651858.CD003230.pub3 Meta-analysis / review
https://doi.org/10.1002/14651858.CD003230.pub3
- Syarifah, A.N., Suryadi, H., Hayun, H., Simamora, A. and others (2023) 'Detoxification of comfrey (Symphytum officinale L.) extract using natural deep eutectic solvent (NADES) and evaluation of its anti-inflammatory, antioxidant, and hepatoprotective properties', Frontiers in Pharmacology, 14, pp. 1012716. doi:10.3389/fphar.2023.1012716 Preclinical
https://doi.org/10.3389/fphar.2023.1012716 - Melnyk, N., Popowski, D., Strawa, J.W., Przygodzinska, K. and others (2023) 'Skin microbiota metabolism of natural products from comfrey root (Symphytum officinale L.)', Journal of Ethnopharmacology, 318(Pt B), pp. 116968. doi:10.1016/j.jep.2023.116968 Preclinical
https://doi.org/10.1016/j.jep.2023.116968 - Trifan, A., Skalicka-Wozniak, K., Granica, S., Czerwinska, M.E. and others (2020) 'Symphytum officinale L.: Liquid-liquid chromatography isolation of caffeic acid oligomers and evaluation of their influence on pro-inflammatory cytokine release in LPS-stimulated neutrophils', Journal of Ethnopharmacology, 262, pp. 113169. doi:10.1016/j.jep.2020.113169 Preclinical
https://doi.org/10.1016/j.jep.2020.113169 - Brown, A.W., Stegelmeier, B.L., Colegate, S.M., Gardner, D.R. and others (2016) 'The comparative toxicity of a reduced, crude comfrey (Symphytum officinale) alkaloid extract and the pure, comfrey-derived pyrrolizidine alkaloids, lycopsamine and intermedine in chicks (Gallus gallus domesticus)', Journal of Applied Toxicology, 36(5), pp. 716-725. doi:10.1002/jat.3205 Preclinical
https://doi.org/10.1002/jat.3205 - Trifan, A., Wolfram, E., Esslinger, N., Grubelnik, A. and others (2021) 'Globoidnan A, rabdosiin and globoidnan B as new phenolic markers in European-sourced comfrey (Symphytum officinale L.) root samples', Phytochemical Analysis, 32(4), pp. 482-494. doi:10.1002/pca.2996 Preclinical
https://doi.org/10.1002/pca.2996 - Nastic, N., Borras-Linares, I., Lozano-Sanchez, J., Svarc-Gajic, J. and others (2020) 'Comparative Assessment of Phytochemical Profiles of Comfrey (Symphytum officinale L.) Root Extracts Obtained by Different Extraction Techniques', Molecules, 25(4), pp. 837. doi:10.3390/molecules25040837 Preclinical
https://doi.org/10.3390/molecules25040837 - Frost, R., MacPherson, H. and O'Meara, S (2013) 'A critical scoping review of external uses of comfrey (Symphytum spp.)', Complementary Therapies in Medicine, 21(6), pp. 724-745. doi:10.1016/j.ctim.2013.09.009 Meta-analysis / review
https://doi.org/10.1016/j.ctim.2013.09.009 - Trifan, A., Opitz, S.E.W., Josuran, R., Grubelnik, A. and others (2018) 'Is comfrey root more than toxic pyrrolizidine alkaloids? Salvianolic acids among antioxidant polyphenols in comfrey (Symphytum officinale L.) roots', Food and Chemical Toxicology, 112, pp. 178-187. doi:10.1016/j.fct.2017.12.051 Preclinical
https://doi.org/10.1016/j.fct.2017.12.051 - Dey, D., Jingar, P., Agrawal, S., Shrivastava, V. and others (2019) 'Symphytum officinale augments osteogenesis in human bone marrow-derived mesenchymal stem cells in vitro as they differentiate into osteoblasts', Journal of Ethnopharmacology, 248, pp. 112329. doi:10.1016/j.jep.2019.112329 Preclinical
https://doi.org/10.1016/j.jep.2019.112329 - Kuchta, K. and Schmidt, M (2020) 'Safety of medicinal comfrey cream preparations (Symphytum officinale s.l.): The pyrrolizidine alkaloid lycopsamine is poorly absorbed through human skin', Regulatory Toxicology and Pharmacology, 118, pp. 104784. doi:10.1016/j.yrtph.2020.104784 Preclinical
https://doi.org/10.1016/j.yrtph.2020.104784 - European Medicines Agency (2011) 'European Union herbal monograph on Symphytum officinale L., radix'. Traditional / reference
https://scholar.google.com/scholar?q=European%20Union%20herbal%20monograph%20on%20Symphytum%20officinale%20L.%2C%20radix - Royal Botanic Gardens, Kew (n.d.). Available at: https://powo.science.kew.org Traditional / reference
https://powo.science.kew.org - Staiger, C (2012) 'Comfrey: a clinical overview', 26(10), pp. 1441--1448. doi:10.1002/ptr.4612 Randomized trial
https://doi.org/10.1002/ptr.4612 - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Vithayathil, M.K. and Edwards, M (2016) 'Comfrey herbal remedy causing second-degree heart block: do not be outfoxed by digitalis', BMJ Case Reports, 2016, pp. bcr2016216995. doi:10.1136/bcr-2016-216995 Clinical study
https://doi.org/10.1136/bcr-2016-216995 - Lin, C.C. and Yang, C.C. and Phua, D.H. and Deng, J.F. and Lu, L.H (2010) 'An outbreak of foxglove leaf poisoning', Journal of the Chinese Medical Association, 73(2), pp. 97-100. doi:10.1016/S1726-4901(10)70009-5 Clinical study
https://doi.org/10.1016/S1726-4901(10)70009-5 - Woodland Trust (2024) 'Foxglove (Digitalis purpurea)'. Available at: https://www.woodlandtrust.org.uk/trees-woods-and-wildlife/plants/wild-flowers/foxglove/ Traditional / reference
https://www.woodlandtrust.org.uk/trees-woods-and-wildlife/plants/wild-flowers/foxglove/
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.